查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1683393

全球泌尿科机器人设备市场 - 2025 至 2033 年

Global Urology Robotics Devices Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球泌尿科机器人设备市场规模达到 67.2 亿美元，预计到 2033 年将达到 285.7 亿美元，在 2025-2033 年预测期内的复合年增长率为 17.7%。

泌尿科机器人设备是先进的手术工具，用于协助外科医生对泌尿系统（包括膀胱、肾臟、前列腺和其他相关器官）进行微创手术。这些设备通常由配备专门仪器的机械手臂、用于增强可视化的高清 3D 摄影机以及外科医生可以精确控制系统的控制台组成。

这些设备可以实现更小的切口、更快的恢復时间、更少的失血和最小的疤痕，从而改善患者的治疗效果，同时保持精细的泌尿外科手术的高精度。

市场动态：

驱动因素与约束因素

技术进步

技术进步透过提高泌尿科手术的精确度、效率和结果，大大推动了泌尿科机器人设备市场的发展。透过增强型机器人系统等创新提供更好的视觉化、微创技术和即时资料分析，外科医生可以更准确、更有控制力地执行复杂的手术。这些进步缩短了患者的恢復时间，最大限度地减少了併发症，并改善了整体手术效果，使机器人设备成为泌尿外科越来越受欢迎的选择。例如，2024 年 9 月，泌尿科机器人设备市场宣布了一项突破性进展，机器人能量疗法领域的全球领导者 EDAP TMS SA 与领先的人工智慧医疗保健公司 Avenda Health 达成合作协议，以彻底改变前列腺癌治疗。透过将 Avenda 的创新 AI 技术 Unfold AI 与 EDAP TMS 的尖端 Focal One 机器人高强度聚焦超音波 (HIFU) 系统相结合，两家公司将推出世界上首个 AI 辅助机器人 HIFU 程式。

此外，这些设备中人工智慧和机器学习的整合可以实现个人化的治疗计划，进一步促进机器人技术在泌尿科护理中的应用。因此，泌尿科机器人设备的需求快速成长，进而带来市场扩张和技术突破。

严格的监管框架

医疗器材（尤其是机器人系统）的审批过程复杂且耗时，通常需要进行大量临床试验、安全评估以及遵守区域和国际标准。这可能会导致产品发布延迟和开发成本增加。因此，这些规定可能会减缓市场扩张，并降低泌尿科新兴尖端机器人技术的整体可用性。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动态

  • 影响因素
    • 驱动程式
      • 技术进步
      • 泌尿系统疾病盛行率不断上升
    • 限制
      • 严格的监管框架
      • 训练有素的专业人员数量有限
    • 机会
      • 策略伙伴关係和合作
    • 影响分析

第五章：产业分析

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第 6 章：依产品类型

  • 机器人手术系统
  • 仪器及配件
  • 其他的

第 7 章：按程序

  • 机器人摄护腺切除手术
  • 机器人膀胱切除术
  • 机器人肾盂成形术
  • 机器人肾臟切除手术

第 8 章：按最终用户

  • 医院
  • 专科诊所
  • 其他的

第九章：按地区

  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 10 章：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 併购分析

第 11 章：公司简介

  • Intuitive Surgical
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售量
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 主要进展
      • 合併与收购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT 分析
  • Asensus Surgical US, Inc.
  • MicroPort Scientific Corporation
  • Titan Medical Inc.
  • Ethicon, Inc.
  • Medtronic
  • CMR Surgical Ltd

第 12 章：附录

简介目录
Product Code: MD9342

The global urology robotics devices market reached US$ 6.72 billion in 2024 and is expected to reach US$ 28.57 billion by 2033, growing at a CAGR of 17.7% during the forecast period 2025-2033.

Urology robotic devices are advanced surgical tools used to assist surgeons in performing minimally invasive procedures on the urinary system, including the bladder, kidneys, prostate, and other related organs. These devices typically consist of robotic arms equipped with specialized instruments, a high-definition 3D camera for enhanced visualization, and a console where the surgeon can control the system with precision.

These devices allow for smaller incisions, faster recovery times, reduced blood loss, and minimal scarring, improving patient outcomes while maintaining high levels of precision in delicate urological surgeries.

Market Dynamics: Drivers & Restraints

Technological Advancements

Technological advancements are significantly driving the urology robotic devices market by improving the precision, efficiency, and outcomes of urological procedures. With innovations like enhanced robotic systems offering better visualization, minimally invasive techniques, and real-time data analytics, surgeons can perform complex procedures with greater accuracy and control. These advancements reduce patient recovery times, minimize complications, and improve overall surgical outcomes, making robotic devices an increasingly popular choice in urology. For instance, in September 2024, A groundbreaking advancement in the urology robotic devices market was announced as EDAP TMS SA, a global leader in robotic energy-based therapies, and Avenda Health, a leading AI healthcare company, have entered into a collaboration agreement to revolutionize prostate cancer care. By integrating Avenda's innovative AI technology, Unfold AI, with EDAP TMS's cutting-edge Focal One robotic high-intensity focused ultrasound (HIFU) system, the companies are set to launch the world's first AI-assisted robotic HIFU procedures.

Additionally, the integration of artificial intelligence and machine learning in these devices allows for personalized treatment plans, further boosting the adoption of robotic technologies in urological care. As a result, the demand for urology robotic devices is rapidly growing, leading to market expansion and technological breakthroughs.

Stringent Regulatory Frameworks

The approval process for medical devices, especially robotic systems, is complex and time-consuming, often requiring extensive clinical trials, safety evaluations, and compliance with regional and international standards. This can lead to delays in product launches and increased development costs. As a result, these regulations can slow market expansion and reduce the overall availability of new, cutting-edge robotic technologies in urology.

Segment Analysis

The global urology robotics devices market is segmented based on the product type, procedure, end-user and region.

Robotic surgery systems segment in the product type is expected to dominate the urology robotics devices market

The robotic surgery systems segment is dominating the urology robotic devices market due to several key factors. Robotic surgery systems offer significant advantages in precision, control, and minimally invasive procedures, which are crucial for complex urological surgeries. These systems allow for enhanced visualization, reduced risk of human error, and quicker recovery times for patients, making them highly attractive to healthcare providers.

As the technology continues to evolve, robotic surgery systems are becoming more sophisticated, offering better outcomes and driving higher adoption rates across hospitals and surgical centers. For instance, in July 2024, Asensus Surgical, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for an expanded indication to treat both adult and pediatric urology patients with the Senhance Surgical System. This expansion highlights the growing dominance of the robotic surgery systems segment, as the Senhance system's advanced technology enables more precise, minimally invasive procedures in urology. Thus, the above factors are expected to hold the segment in the dominant position.

Geographical Analysis

North America is expected to dominate the urology robotics devices market

North America is dominating the urology robotic devices market due to several key factors. The region has a strong healthcare infrastructure with advanced medical facilities and a high adoption rate of cutting-edge technologies, including robotic surgery systems. Hospitals and surgical centers in North America are more likely to invest in expensive robotic systems due to their ability to improve patient outcomes, reduce recovery times, and minimize surgical complications.

Furthermore, North America has a well-established reimbursement structure for robotic surgeries, making it financially feasible for healthcare providers to adopt these technologies. Companies are receiving FDA approvals for their advanced innovations which are driving the region's market growth.

For instance, in July 2024, Asensus Surgical, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the indication of its Senhance Surgical System to treat both adult and pediatric urology patients. This approval reflects the region's continuous innovation and adoption of advanced medical technologies, positioning North America at the forefront of robotic-assisted surgery. North America remains a global leader in transforming healthcare through robotics, setting new standards for precision, efficiency, and patient outcomes in urological care. The region also benefits from a large, aging population with an increasing demand for urological procedures, further fueling the growth of robotic devices.

Competitive Landscape

The global market players in the urology robotics devices market are Intuitive Surgical, Asensus Surgical US, Inc., MicroPort Scientific Corporation, Titan Medical Inc., Ethicon, Inc., Medtronic and CMR Surgical Ltd., among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
  • Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global urology robotics devices market report would provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Procedure
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advancements in Technology
      • 4.1.1.2. Increasing Prevalence of Urological Disorders
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Frameworks
      • 4.1.2.2. Limited Availability of Trained Professionals
    • 4.1.3. Opportunities
      • 4.1.3.1. Strategic Partnerships and Collaborations
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Force Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Robotic Surgery Systems*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Instruments and Accessories
  • 6.4. Others

7. By Procedure

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Robotic Prostatectomy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Robotic Cystectomy
  • 7.4. Robotic Pyeloplasty
  • 7.5. Robotic Nephrectomy

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Specialty Clinics
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. Latin America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Mexico
      • 9.4.6.2. Brazil
      • 9.4.6.3. Argentina
      • 9.4.6.4. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Intuitive Surgical*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue's
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals etc.
    • 11.1.5. SWOT Analysis
  • 11.2. Asensus Surgical US, Inc.
  • 11.3. MicroPort Scientific Corporation
  • 11.4. Titan Medical Inc.
  • 11.5. Ethicon, Inc.
  • 11.6. Medtronic
  • 11.7. CMR Surgical Ltd

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us